Protein transduction domains (PTDs) are small peptides that facilitate the transduction of large molecules such as polyproteins, DNA and viruses into a eukaryotic cell. Here, we demonstrated that a novel PTD (HP4) derived from herring protamine appeared to enter C6Bu1 rat glioma cell lines more rapidly than other known PTDs such as Tat, Antp and Hph-1. Moreover, HP4 significantly enhanced in vitro transduction of recombinant adenoviruses (rAds) into various cancer cell lines, mesenchymal stem cells (MSCs) and dendritic cells, which are relatively resistant to rAd infection. Enhancement of rAd delivery into C6Bu1 and MSCs by HP4 is 20 and 7 times higher than that by Tat, respectively. The increase in the expression of rAd encoding IL-12N220L by HP4 is proportional to its antitumor effect in the ex vivo transduced mouse colon cancer model. Thus, these results suggest that HP4 could be utilized to improve the transduction efficiency of rAd, resulting in enhanced efficacy of rAd-mediated gene therapy, especially for ex vivotransduced cell therapy.
Introduction
Protein transduction domains (PTDs), also called cellpenetrating peptides or membrane translocating sequences, are small peptides that are composed of less than 20 amino acids and can traverse the plasma membrane of many types of mammalian cells. Transcriptional activator (Tat) protein of human immunodeficiency virus 1 was first shown to cross the cell membrane and localize in the nucleus when added exogenously. 1 Subsequent studies have shown that the sequence responsible for the cellular uptake of Tat protein is RKKRRQRRR, 2 which successfully delivered fusion proteins (up to 120 kDa) in vivo into a variety of mouse tissues, including the brain. 3 In addition to human immunodeficiency virus 1 Tat protein, Antp derived from Drosophila Antennapedia homeodomain, Hph-1 derived from human transcription factor and VP22 derived from herpes simplex virus type 1 were reported to translocate the membrane and accumulate in the nucleus. [4] [5] [6] The cationic residues of PTDs are generally believed to play a crucial role in translocation, but the detailed mechanism of PTD translocation is still a matter of debate. Although early reports provided evidence that PTD uptake occurs in an endocytosis-independent manner, 2, 7, 8 recent data suggest that endocytosis plays a major role in the uptake of Tat PTD. 9, 10 The discovery of PTDs has made it possible to transfer large molecules into living cells by penetrating the impermeable plasma membrane barrier. A number of studies have examined the application of PTD-conjugated proteins to many disease models. Hph-1-ctCTLA-4 fusion protein, which is the PTD-fused cytoplasmic domain of CTLA-4, facilitated intranasal delivery and prevented allergic inflammation in vivo. 5 PTDs have also been used to introduce tumor suppressors or pro-apoptotic proteins, such as p53, DP1 and Smac, directly into growing tumors. [11] [12] [13] Several small molecules such as fluorescent dyes and low-molecular-weight pharmaceuticals have also been conjugated with PTDs to achieve efficient cellular transduction. Polyarginine R7 was used as a transducible conjugate with cyclosporin A, effectively suppressing cutaneous inflammation.
14 Also, PTD has been used as a gene delivery vehicle. Tat PTD reportedly facilitated the internalization of DNA in the form of Tat/DNA conjugates. 15, 16 Tat/DNA complexes were stabilized by electrostatic interactions between the positively charged Tat PTD and the negatively charged phospho groups in DNA. Moreover, arborizing Tat PTD was reported to further improve DNA transfection. 17 Furthermore, dual conjugation of Tat-p53 therapeutic protein with the ligand of CXCR4, which is a highly expressed chemokine receptor on tumor cells, resulted in strong specificity for PTD-mediated internalization. 11 This result implies therapeutic potential for PTD-mediated target cell-specific delivery.
Recombinant adenoviruses (rAds) have been widely used in several gene therapy applications, particularly for cancer gene therapy and immunotherapy. These broad applications result from several important advantages of rAd over other vectors, including broad tropisms, efficient transduction in dividing and non-dividing cells, high level of transgene production, high immunogenicity and low risk of insertional mutagenesis. However, the utility of rAd is limited by low transduction efficiency in certain types of cancer cells and stem cells that express low levels of the primary rAd receptor, coxsackievirus and adenovirus receptor. 18 Therefore, many studies have been designed to improve rAd-mediated gene delivery into these cells. One such approach is the modification of rAd by the attachment of ligand for cellular receptors and incorporation of chimeric envelope glycoprotein. 19, 20 Polycations or cationic lipids, such as polybrene, protamine sulfate (PS), N-(1-[2,3-dioleoyloxy]propyl)-N,N,Ntrimethylammonium methyl sulfate and lipofectamine, have generally been used to facilitate the entry of viral particles into target cells. [21] [22] [23] In addition, PTDs, such as Tat 48À60 and Antp, were reported to enhance rAd entry and improve their therapeutic efficacy. 24 However, a high concentration (0.5 mM) of PTDs is required to increase transduction efficiency by approximately 10-fold.
Mesenchymal stem cells (MSCs), a very small population of the total bone marrow cells (0.001-0.01%), are multipotent non-hematopoietic progenitor cells. 25 They have the ability to differentiate into cells of mesodermal lineage, including adipocyte, chondrocyte, osteocyte and myocyte, implying that MSCs are attractive therapeutics in regenerative medicine and tissue engineering. 25 Recent researches revealed that MSCs have tumor tropism in the glioma model, implying that MSCs could be a potent vehicle for targeted cancer therapy, especially for glioma therapy. 26 Taken together, regenerative medicine, and cell and gene therapy applications that target MSCs offer great potential for the treatment of many kinds of diseases. Despite these promises, clinical success has been limited by poor rates of gene transfer and poor levels of gene expression, indicating the need for an efficient gene transfer system into MSCs for therapeutic applications in gene-modified vaccines.
Protamines are small and arginine-rich nuclear proteins that compact the genomic DNA structures by binding to them, and have a role in DNA delivery to the nucleus of the egg during fertilization. 27 Protamines have become one of the promising agents for intracellular delivery of not only exogenous DNA but also rAds. 27, 28 The main sources of protamines are sperms of various mature fish such as herring, salmon and trout. Salmon and herring protamine showed similar transfection level, but higher than that of trout protamine. 29 It was also reported that salmon protamine has a Tat-like PTD domain, which has the property of intracellular delivery of proteins. 30 In this study, we hypothesized that herring protamine has an arginine-rich PTD domain and identified a novel PTD, HP4, that enhanced rAd delivery into several cancer cell lines, MSCs and dendritic cells (DCs) to a greater degree than herring PS itself, resulting in enhanced antitumor effect of therapeutic rAd (rAd/IL-12N220L) in an ex vivo-transduced mouse colon cancer model. Our results suggest that HP4 could strengthen the efficacy of rAd-mediated gene therapy by increasing the transduction efficiency of rAd to tumor cells or MSCs.
Materials and methods

Mice
Six-to eight-week-old BALB/c female mice were purchased from Charles River Breeding Laboratories (Shizuoka, Japan) and housed in a specific pathogen-free environment in an internally approved vivarium at the institute. 
Peptides
Cell culture
The following cell lines were purchased from American Type Culture Collection (Manassas, VA): A375, one of a series of cell lines established from solid melanoma tumors from a 54-year-old female; CT26, a chemically induced colon carcinoma line derived from BALB/c mice; B16F10, a melanoma line derived from C57BL/6 mice; U-87MG, a human glioma line; HeLa, a human cervical carcinoma line; A549, a human lung carcinoma line; and K562, a human chronic myeloid leukemia line. C6Bu1 cells, a rat glioma line, were kindly provided by Dr Pann-Ghill Suh (POSTECH, Korea). A375, B16F10, U-87MG, HeLa and C6Bu1 cells were maintained in DMEM (BioWhittaker, Walkersville, MD) and CT26, A549 and K562 cells were maintained in RPMI (BioWhittaker) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT) and 1 g each of penicillin and streptomycin (Life Technologies Inc., Grand Island, NY) per 100 ml.
Human umbilical cord blood-derived MSCs (UCBMSCs) were kindly provided by MEDIPOST Inc. (Seoul, Korea) and bone marrow-derived MSCs (BM-MSCs) were purchased from FCB-PHAMICELL Co. Ltd (Seongnam, Korea). Human adipose tissue-derived MSCs (AT-MSCs) were isolated from subcutaneous adipose tissue that was harvested from donors undergoing elective surgical procedures. AT-MSCs were isolated from adipose tissue and cultured as described previously. 31, 32 UCB-MSCs, BM-MSCs and AT-MSCs were cultured in a-MEM (GIBCO, Grand Island, NY), DMEM with low glucose (BioWhittaker) and DMEM with high glucose (BioWhittaker) medium supplemented with 10% fetal bovine serum and 1 g each of penicillin and streptomycin per 100 ml, respectively. To generate bone marrowderived dendritic cells (BMDCs), bone marrow cells were flushed from the tibias and femurs of female BALB/c mice and then depleted of red blood cells (RBCs) with RBC lysing buffer (Sigma, St Louis, MO). Cells were resuspended in complete medium (RPMI supplemented with 10% fetal bovine serum and 1 g each of penicillin and streptomycin per 100 ml) and cultured in tissue culture dishes for 90 min. Non-adherent cells were collected and cultured in 100 mm culture dishes containing 6 ml of complete medium supplemented with mouse granulocyte macrophage colony-stimulating factor (mGM-CSF) (10 ng ml
À1
) and mIL-4 (10 ng ml
). On days 3 and 5, 2 ml of complete medium supplemented with mGM-CSF (10 ng ml
) and mIL-4 (10 ng ml À1 ) was added. On day 7, non-adherent cells were collected and used as the source of DCs in subsequent experiments. The phenotype of the enriched DC was confirmed by flow cytometric expression of CD80, CD86, CD40, CD11c and MHC class II.
Construction of replication-defective adenoviral vectors
Recombinant replication-defective adenoviruses were generated using the AdEasy Vector System (QBiogene) as previously described. 33 Briefly, the cDNAs of enhanced green fluorescent protein (EGFP) and murine IL-12N220L were subcloned into the adenoviral shuttle vector, pShuttleCMV. After recombination with the adenoviral backbone vector, pAdEasy, in Escherichia coli BJ5183, the rAds were generated and expanded in 293 cells. Adenoviral titers were determined using the tissue culture infectious dose 50 methods according to the supplier's protocol (QBioGene, Irvine, CA). All the concentrations of rAds indicated in experimental descriptions are based on a multiplicity of infection (MOI) of PFU/cell.
In vitro adenovirus transduction
Cells were seeded into 48-well plates at 3 Â 10 4 cells per well and incubated overnight at 37 1C. rAd/EGFP at various MOIs (l00 MOI for C6Bu1, U-87MG, A549, K562, A375, MSCs and BMDCs or 300 MOI for CT26, B16F10 and HeLa) was diluted in serum-free medium to achieve a 2 Â virus dilution. PTD was similarly diluted into serum-free medium to yield 2 Â dilutions. Virus and PTD mixtures were combined at a 1:1 ratio and allowed to incubate for 30 min at room temperature. Cell monolayers were washed and overlaid with 150 ml of virus/PTD mixture. After 2 h incubation in a CO 2 incubator at 37 1C, the virus/PTD complex was removed and 300 ml of fresh serum-containing medium was added. For suspension cells such as K562 or BMDCs, 20% serum-containing medium was added to cells without changing the medium. Cells were then incubated for an additional 46 h before green fluorescent protein (GFP) expression was analyzed. Gene transduction efficiency was analyzed using flow cytometry.
Ex vivo-transduced tumor model CT26 cells were seeded at an initial density of 2 Â 10 6 in a 100-mm dish and incubated overnight at 37 1C. The cells were infected with adenovirus at an MOI of 300 in the presence or absence of 100 mM PTD (Tat 48À60 or HP4) in 4 ml of serum-free medium at 37 1C for 2 h. Culture medium was replaced and cells were incubated for an additional 4 h. Then, the cells were trypsinized, washed and subcutaneously injected into BALB/c mice (5 Â 10 5 cells per mouse). At 24 h after tumor injection, serum samples were collected and the expression level of IL-12 in the serum was measured using IL-12p70 ELISA kits (R&D Systems, Minneapolis, MN). Tumor size was measured at least twice a week with a digital caliper for two-dimensional longest axis (L, in mm) and shortest axis (W, in mm), and tumor volume was calculated using the following formula:
)/2. Mice bearing tumors that exceeded 15 mm in two perpendicular diameters or 20 mm in one diameter were killed for ethical reasons according to institutional guidelines.
Peptide internalization
Cells were seeded into 48-well plates at 3 Â 10 4 cells per well and incubated overnight at 37 1C. Cell monolayers were washed and overlaid with PTD-FITC diluted in DMEM without serum to achieve the proper concentration. After 30 min incubation in a CO 2 incubator at 37 1C, cells were washed twice with PBS. Peptide internalization was assessed by FACS-Calibur flow cytometry using CellQuest software (Becton Dickinson, Tokyo, Japan). A total of 10 000 events were acquired by forward and side scatter gating to exclude cell debris.
Cytotoxicity test
C6Bu1 cells were seeded at an initial density of 3 Â 10 4 in a 96-well plate and incubated overnight at 37 1C. The cells were treated with increasing concentrations of Tat 48À60 , Hph-1 or HP4. After 24 h incubation, 10 ml MTT (5 mg ml À1 ; Sigma) was added. Following 4 h of incubation at 37 1C, the produced formazan was dissolved with acid-isopropanol solution (0.04 N HCl/isopropanol). The absorbance at 570 nm was determined by a microplate reader.
The cytotoxic dose of PTD-FITCs was determined on the basis of morphological change of treated cells and percentage of detached cells in the whole region using light microscopy and confirmed by flow cytometry. The concentration of PTD-FITC showing less than 80% viable cells was considered as a cytotoxic dose in analysis by light scatter (FSC/SSC).
Statistical analysis
To measure statistical difference between groups, Student's t-test was used. Survival analysis was performed with the Kaplan-Meier method, with comparison of survival curves by using the log-rank test. P-values less than 0.05 were considered to indicate a statistically significant difference.
Results
Identification of a novel PTD (HP4) derived from herring protamine To investigate whether herring PS affects the transduction efficiency of rAd, three tumor cell lines (B16F10 mouse melanoma, A375 human melanoma and C6Bu1 rat glioma cells) were infected with rAd/EGFP preincubated with various concentrations of PS. When the GFP expression level was analyzed by flow cytometry at 48 h after infection, PS was observed to dose-dependently enhance GFP expression by facilitating rAd transduction (Figure 1a) . In particular, transgene expression increased by 4.5-fold (A375), 10-fold (B16F10) and 3-fold (C6Bu1) at 50 mg ml À1 of PS compared with virus alone. Our results are consistent with the previous report that PS increased the transduction of rAd 5-to 10-fold in various tumor cell lines. 28 To determine the key domain of herring protamine responsible for rAd transduction, we constructed six herring protamine derivatives (HP1-6) by sequentially dividing the full amino-acid sequence of herring protamine into 14-amino-acid peptides that overlapped by 10 or 11 residues (Figure 1b) . Each peptide was evaluated for its ability to enhance the transduction efficiency of rAd/ EFGP into C6Bu1 cells, which are known to be resistant to adenoviral infection. Tat 49À57 , Tat 48À60 and Hph-1 were used as positive controls. 2, 5, 24 Among the HP derivatives, HP4 had the highest transduction efficiency for rAd (28 and 70% of GFP-positive cells at 50 and 100 mM, respectively), followed by HP6 (Figure 2a) . As expected, 100 mM Tat 48À60 resulted in 3.6% GFP-positive cells. Thus, HP4 exhibited about 20 times higher rAd transduction efficiency than 100 mM Tat 48À60 . Taken together, HP4 enhances rAd transduction efficiency to a greater degree than herring PS as well as other known PTDs such as Tat 49À57 , Tat 48À60 and Hph-1.
To investigate the optimal dose of HP4, rAd/EGFP (100 MOI) were preincubated with various concentrations of PTDs and then infected into C6Bu1. As expected, all PTDs tested enhanced GFP expression in a dosedependent manner (Figure 2b) . At 100 mM HP4, GFP was detected in about 80% of tumor cells, whereas it was detected in less than 20% of tumor cells even at 300 mM Tat 48À60 or Hph-1. Our results are similar to previous report that Tat 48À60 increased the transduction efficiency of rAd by approximately 10-fold at optimal concentration (500 mM) compared with virus alone. 24 From a quantitative point of view, 100 mM Hph-1 or 300 mM Tat 48À60 was required to achieve 5% transduction, concentrations that are 33-or 100-fold higher than HP4 (3 mM), respectively. To investigate the optimal MOI of rAd in the presence of 100 mM HP4, the transduction level was assessed at various doses of rAd (10-100 MOI). As shown in Figure 2c , HP4 resulted in higher levels of transduction than Tat 48À60 and Hph-1 at all doses of rAd tested. These results indicate that co-treatment of rAd with HP4 can markedly enhance the transduction efficiency of rAd, thereby reducing the rAd titer by more than 30-and 10-fold to achieve the same level of rAd transduction efficiency compared to Tat 48À60 and Hph-1, respectively.
To identify the minimum amino-acid sequence of HP4 required for rAd transduction, we synthesized HP4 derivatives and evaluated their effects on rAd transduction. Deletion of two or five amino-acid residues from the amino terminus of HP4 significantly reduced rAd transduction (more than 95%) relative to the original HP4 sequence (Figure 2d ), indicating that 12 amino acids of HP4 are insufficient for rAd transduction.
Internalization kinetics and cytotoxicity of HP4
To more precisely examine the characteristics of HP4 internalization, C6Bu1 cells were treated with synthetic fluorescence-labeled HP4 for 30 min and the internal FITC level was measured by flow cytometry. Other PTDs (Hph-1-FITC, Tat-FITC and Antp-FITC) and irrelevant peptide GP 61À80 -FITC were used as controls. HP4-FITC exhibited fluorescence intensity 2.5-to 15-fold higher than other PTD-FITCs at 100 mM (Figure 3a) . When the kinetics of PTD internalization were analyzed, the rate of cellular uptake of HP4-FITC appeared to be faster than that of other PTD-FITCs (Figure 3b ). The fluorescence intensity of HP4-FITCs at 10 min appeared to be higher than the fluorescence intensity of other PTDFITCs at 60 min. These results indicate that HP4, a novel PTD, has faster and higher translocation ability into the C6Bu1 cell line than other known PTDs.
To investigate the role of the two threonines in HP4, these residues were substituted with anionic or cationic amino acids. Among them, an HP4 derivative with anionic aspartic acids (HP4DD-FITC) slightly reduced the cellular uptake (Figure 3c ). On the other hand, replacing the two neutral threonines with two cationic amino acids such as arginine (HP4RR-FITC) or lysine (HP4KK-FITC) produced a sevenfold increase in cellular uptake at 10 mM. However, severe cytotoxicity was detected when these PTDs were used at 30 mM. It is worth noting that HP4KK-FITC shows toxicity at 100 mM, indicating that it is less toxic than HP4RR-FITC and HP4RK-FITC.
To determine the non-cytotoxic dose range of PTDs, we treated C6Bu1 cells with various doses of PTDs for 24 h and analyzed cell viability using an MTT assay. We found only a slight decrease of viability (10%) in cells treated with 300 mM Tat (Figure 3d) . In contrast to Tat, HP4 did not induce any cytotoxic effect on target cells even at 300 mM, implying that HP4 could be safely used in rAd transduction.
Enhanced rAd transduction efficiency of cancer cell lines, MSCs and DCs by HP4
To investigate the effect of HP4 on the transduction efficiency of rAd in various mouse and human cancer cell lines such as B16F10, CT26, HeLa, U-87MG, A549, K562 and A375, these cells were transduced by rAd/ EGFP (100 or 300 MOI) in the presence or absence of 100 mM PTD. The MOI of rAd used to transduce each cell line in this experiment was the representative titer showing the maximum efficacy of PTDs based on our preliminary results using different MOIs of 30-300 (data not shown). As expected, rAd-mediated transgene expression was significantly increased by HP4 co-treatment compared with that by Tat 48À60 in all cancer cell lines (Figure 4a ). The relative increase in transduction level by HP4 was different in each cell type depending on its susceptibility to Ad infection. In addition, we tested whether HP4 could overcome the low rAd infectivity of MSCs or DCs. Human UCB-MSCs, BM-MSCs, ATMSCs and mouse BMDCs were treated with rAd/EGFP (100 MOI) in the presence or absence of 100 mM PTD. In contrast to Tat, which showed only a slight increase, HP4 dramatically enhanced the transduction level of MSCs or DCs by 10-or 5-fold over rAd alone, respectively (Figures  4b and c) . These results imply that HP4 could be used for ex vivo genetically modified cell-based therapy.
Enhanced antitumor effect of rAd expressing IL-12N220L by co-treatment with HP4 To apply the enhanced rAd transduction efficiency of tumor cells by HP4 to an ex vivo-transduced tumor model, CT26 cells infected with rAd/IL-12N220L (300 MOI) with or without PTD (100 mM HP4 or Tat 48À60 ) were injected into syngeneic BALB/c mice. IL-12N220L was previously shown to have a stronger antitumor effect than wild-type IL-12. [33] [34] [35] When the serum IL-12 level was determined by enzyme-linked immunosorbent assay at 24 h after tumor injection, the expression level of this transgene was increased 33-fold by HP4 compared with Tat 48À60 (Figure 5a ). Consistent with the IL-12 levels, co-treatment of rAd/IL-12N220L with HP4 significantly increased the survival rate (80%) compared to Tat 48À60 and IL-12N220L alone (40 and 20% respectively; Figure 5b ).
Discussion
A disadvantage of rAd-mediated gene therapy is that it is restricted to target cells that express coxsackievirus and adenovirus receptor (CAR). PTDs, such as Tat 48À60 and Antp, have been reported to improve CAR-independent delivery of rAd. 24 However, high concentrations (0.5 mM) of PTD, possibly resulting in toxicity, were required for only about a 10-fold increase in the transduction level compared with the virus alone. In this study, a novel PTD (HP4) shows about 20-fold higher rAd transduction efficiency than Tat 48À60 at various concentrations. Also, the use of HP4 can significantly reduce the PTD concentration (by 100-fold) required to achieve maximum rAd transduction by Tat 48À60 (5%). Consistent with its in vitro transduction efficiency, HP4 significantly enhanced the antitumor effect of rAd/IL-12N220L in an ex vivotransduced CT26 colon cancer model.
As in vivo rAd injection on established tumor would be more informative for a clinical setting than preinfected tumor model, we directly injected rAd/IL-12N220L with or without PTD to established tumor. Unexpectedly, we observed a slight increase in serum and tumor IL-12 expression in HP4-treated mice, followed by antitumor effect similar to that of rAd alone (data not shown). This discrepancy in the transduction effect of HP4 between in vitro and in vivo tumor models could be explained as follows. As PTD has a role as a molecular adaptor linking the rAd and cell membrane, the initial interaction between PTD-rAd complex and cell membrane is a critical and rate-determining step. It is likely that this interaction could be competitively inhibited by other molecules having a negative charge. Actually, rAd transduction efficiency of PTD into target cells was significantly reduced when serum-containing medium was used instead of serum-free medium. In an in vivo environment, especially in a tumor environment, many kinds of proteins may compete with cell membranes to interact with PTDrAd complexes, and finally inhibit the PTD-mediated intracellular rAd delivery. Alternatively, intratumorally injected PTD-rAd mixture might be rapidly diluted and disassociated in vivo, resulting in loss of PTD effect.
In principle, the common feature of most PTDs is the high content of basic amino acids. Cationic residues in PTDs, such as arginine and lysine, might be important for contact with a negatively charged cargo molecule and the cell membrane. Substitution of a non-charged glutamine residue with alanine in Tat 49À57 modestly decreased cellular internalization, whereas substitution of any basic residue with alanine decreased the uptake by 70-90%. 36 However, polyarginine peptides that are longer than 10-mer (R12, R14 and R16) had less efficient cellular uptake than 8-or 9-mer polyarginine peptides (R8 or R9), indicating that the charge itself is not sufficient for optimal translocation of PTDs. 8, 37 It is likely that the diminished transduction ability of polyarginines that are longer than 10-mer might result from severe toxicity induced by a large number of sequential arginines. 37 In our study, replacing two threonines in HP4 with arginines (HP4RR-FITC and HP4RK-FITC) increased rAd transduction efficiency at a lower concentration (10 mM), which is similar to the previous report that replacement of non-charged amino acids with arginines increased the internalization efficiency of Tat 49À57 . 36 However, both replacements caused severe toxicity in the treated cells, even at 30 mM. Considering both rAd transduction efficiency and toxicity, the interruption of sequential arginines by these two threonines may be necessary for the optimal transduction ability of HP4 without cytotoxicity.
In addition, we analyzed the a-helical wheel structure of HP4 using a program called 'EMBOSS Pepwheel' to investigate the secondary structure of HP4. In contrast to other PTDs derived from herring protamine (HP1-3, 5, 6), the eight arginines of HP4 were located on one side of the a-helical section. These eight locally distributed arginines might produce a synergistic charge force and promote the translocation of HP4, similar to the previous report that synthetic PTDs in which the amino acids were arranged to preferentially allow bipolar placement of arginines in an a-helical structure showed high protein transduction potential and that the existence of a hydrophobic alanine face opposite the arginine face in the a-helical structure improved transduction efficiency by stabilizing the a-helical structure of synthetic PTD. 38 However, the a-helical structure of HP4 does not have a hydrophobic face as well as alanine residues. Also, other HP4 derivatives that were designed to form a bipolar ahelical structure with arginine and alanine faces could not further improve the transduction efficiency (data not shown). It is worth noting that Tat 48À60 and Hph-1 do not have bipolar distribution in their a-helical structures, even though they were already known as efficient protein delivery vehicles.
The lengths of the peptides may also be a critical factor for PTD efficiency. Deletion of an arginine residue from the amino terminus or carboxyl terminus of Tat 49À57 drastically decreased the internalization efficiency of PTD (70%), indicating that the nine-amino-acid sequence (RKKRRQRRR) of Tat 49À57 is the minimal PTD of the Tat protein. 36 Similarly, deletion of two (HP4-1, RRPRRRTTRRRR) or five (HP4-2, RRRTTRRRR) amino-acid residues from HP4 resulted in a significant at 300 MOI for 6 h in vitro, infected cells were trypsinized, washed and subcutaneously injected into syngeneic BALB/c mice (5 Â 10 5 cells per mouse). At 24 h after tumor cell injection, serum samples were taken and the expression level of IL-12 in the serum (a) was measured by enzyme-linked immunosorbent assay. The survival rate (b) was determined at least twice a week. Each data point represents the average concentration (ng ml
À1
) or survival rate (%)±s.e.m. of five mice. Data are representative of two independent experiments with similar results. Statistical significance was determined using the Kaplan-Meier analysis followed by log-rank test. *Po0.05 compared with virus alone.
loss of rAd transduction ability (95 or 98% loss, respectively) compared to HP4, indicating that the length of the peptide is one of the important characteristics of HP4.
Our results clearly demonstrated that HP4, a novel PTD, significantly increased rAd transduction efficiency into various cancer cell lines without severe toxicity and that HP4 is applicable to rAd-mediated cancer gene therapy to increase antitumor activity. Furthermore, HP4 could be an innovative tool for ex vivo engineering of primary cells expressing low level of CAR such as MSCs and DCs, which are widely applicable for gene-modified cell therapy. Thus, we suggest that HP4 may be of great use for rAd-mediated cell-based therapy in the future.
